Clinical trial NCT06578325: Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
Official title: Effects of Thai Dance Meditation Exercise on Renal and Cerebrovascular Function in Elderly With Diabetic Kidney Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetic Kidney Disease
Keywords: Diabetic kidney disease
Cerebrovascular reactivity
Renal function
Thai dance meditation
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2024-08-29
Enrollment: 40
Sex: ALL
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Elderly with diabetic kidney disease who practiced Thai dance meditation training more favorable adaptations than normal daily life in improving glycemic control, kidney function, vascular function and cerebrovascular function.

Detailed description: This cross-sectional study was to compare glycemic control, kidney function, vascular function, cerebrovascular function, physical fitness and quality of life between elderly with diabetic kidney disease who practiced Thai dance meditation training and normal daily life.

Eligibility criteria: Inclusion Criteria:

* The inclusion criteria included diabetic kidney disease (DKD) (as defined by the KDIGO (Kidney Disease Improving Global Outcomes 2012), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, albumin-to creatinine ratio (ACR): A3 \[\>300 mg/day; ACR, \>300 mg/g (\>30 mg/mmol)\], GFR category 3 (moderately decreased) has now been divided into categories G3a \[45-59 mL/ min1 /(1.73m2) and G3b \[30 -44 mL/ min1/(1.73 m2) which represent mildly to moderately decreased function and moderately to severely decreased function and no previous exercise training in the past 6 months.
* All participants were free from diabetic retinopathy, severe diabetic neurophathy, severe cardiovascular and cerebrovascular diseases.
* Participants had Montreal Cognitive Assessment - Thai (MoCa-T) scores between 18 24 points.
* Not having uncontrolled high blood pressure (Systolic blood pressure; SBP) \>159 mmHg and Diastolic blood pressure; DBP) \> 99 mmHg

Exclusion Criteria:

- Participants were excluded if they dropped out or completed less than 80% of the training schedule

Primary outcomes:
measure: Blood pressure
timeFrame: Change from baseline systolic blood pressure, diastolic blood pressure, and mean arterial pressure at 12 weeks.]
measure: Heart rate
timeFrame: Change from baseline heart rate at 12 weeks
measure: Body fat
timeFrame: Change from baseline body fat at 12 weeks
measure: Muscle mass and Weight
timeFrame: Change from baseline muscle mass and weight at 12 weeks.
measure: Arterial stiffness
timeFrame: Change from baseline brachial-ankle pulse wave velocity at 12 weeks
measure: Macro vascular function
timeFrame: Change from baseline brachial artery flow-mediated dilatation at 12 weeks
measure: Renal function
timeFrame: Change from baseline Blood urea nitrogen at 12 weeks.
measure: Intrarenal artery
timeFrame: Change from baseline renal arterial resistive index (RI) at 12 weeks.
measure: Post Occlusive Reactive Hyperemia; PORH
timeFrame: Change from baseline Post Occlusive Reactive Hyperemia; PORH at 12 weeks.
measure: Cerebral blood flow
timeFrame: Change from baseline cerebral blood flow at 12 weeks
measure: Cerebrovascular conductance index
timeFrame: Change from baseline cerebrovascular conductance index at 12 weeks
measure: Cerebrovascular reactivity index
timeFrame: Change from baseline cerebrovascular reactivity index at 12 weeks
measure: Arterial compliance
timeFrame: Change from baseline Arterial compliance at 12 weeks
measure: Pulsatility index
timeFrame: Change from baseline Pulsatility index at 12 weeks.] 12.Montreal Cognitive Assessment
measure: Montreal Cognitive Assessment
timeFrame: Change from baseline Montreal Cognitive Assessment at 12 weeks.]
measure: Mini-Mental State Examination
timeFrame: Change from baseline Mini-Mental State Examination at 12 weeks.]
measure: Trail Making Test-B
timeFrame: Change from baseline Trail Making Test-B at 12 weeks
measure: Fasting blood sugar
timeFrame: Change from baseline fasting blood sugar at 12 weeks.]
measure: Glycosylated hemoglobin
timeFrame: Change from baseline Glycosylated hemoglobin at 12 weeks.]
measure: Homeostasis Model Assessment of insulin resistance
timeFrame: Change from baseline Homeostasis Model Assessment of insulin resistance at 12 weeks.]
measure: Creatinine
timeFrame: Change from baseline creatinine at 12 weeks.]
measure: estimate Glomerular filtration rate
timeFrame: Change from baseline estimate Glomerular filtration rate at 12 weeks.]
measure: Cystatin C
timeFrame: Change from baseline blood urea nitrogen at 12 weeks
measure: Urine albumin creatinine ratio
timeFrame: Change from baseline urine albumin creatinine ratio at 12 weeks.
measure: Stroop test
timeFrame: Change from baseline Stroop test in second at 12 weeks.
Secondary outcomes:
measure: Waist circumference
timeFrame: Change from baseline waist circumference at 12 weeks]
measure: .Flexibility testing
timeFrame: Change from baseline Chair sit & reach at 12 weeks.]
measure: Muscle strength testing
timeFrame: Change from baseline arm-curl and chair stand at 12 weeks.]
measure: Muscle strength testing
timeFrame: Change from baseline arm-curl and chair stand at 12 weeks.]
measure: Balance testing
timeFrame: Change from baseline time up and go at 12 weeks.]
measure: Cardiopulmonary fitness
timeFrame: Change from baseline 6-minutes walk at 12 weeks.]
measure: Lipid profile
timeFrame: Change from baseline Nitric oxide at 12 weeks.] cholesterol, triglyceride, high density lipoprotein, and low density lipoprotein at 12 weeks.]
measure: Interleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase.
timeFrame: Change from baselineInterleukin-6 (IL-6), Tumor necrosis factor-alpha (TNF- α), Brain derived neurotrophic factor, Malondialdehyde, Superoxide Dismutase. at 12 weeks.]
measure: Nitric oxide
timeFrame: Change from baseline Nitric oxide at 12 weeks.
measure: Quality of life in patients with chronic kidney disease
timeFrame: Change from baseline at 12 weeks.
measure: Flexibility testing
timeFrame: Change from baseline back scratch at 12 weeks.
measure: Muscle strength testing
timeFrame: Change from baseline chair stand at 12 weeks.]
measure: Body mass index (BMI)
timeFrame: Change from baseline BMI at 12 weeks.
Other outcomes:
Locations:
city: Pathum Wan
country: Thailand
facility: Faculty of Sports Science, Chulalongkorn University
state: Bangkok
Study officials:
affiliation: Chulalongkorn University
name: Daroonwan Suksom, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References: